Sage Journals: Discover world-class research

Abstract

β-Propeller protein–associated neurodegeneration (BPAN) is a rare, X-linked condition caused by pathogenic variants in the WDR45 gene that result in a defect of autophagy. Classified as a disorder of neurodegeneration with brain iron accumulation, β-propeller protein–associated neurodegeneration is associated with severe neurologic impairments. With the anticipation of future therapeutic trials, this project characterizes the family's perspective of the impact of disease and defines Health Concepts (HC).

Children with a molecularly confirmed diagnosis of β-propeller protein–associated neurodegeneration were enrolled in a prospective natural history study. We administered the Vineland Adaptive Behavior Scales–Third Edition and provided health-related quality of life questionnaires to 42 caregivers. Questionnaires included Pediatric Quality of Life Inventory–Generic Core and Pediatric Quality of Life Inventory–Family Impact modules, Caregiver Priorities and Child Health Index of Life with Disabilities, and Caregiver TBI-CareQoL.

The Vineland Adaptive Behavior Scales–Third Edition (n = 42) captured the family's perspective that communication was more affected compared with socialization, activities of daily living (ADL), and motor skills (P < .0001, P < .0001, P = .0053, respectively). Similarly, on the Caregiver Priorities and Child Health Index of Life with Disabilities (n = 26), Pediatric Quality of Life Inventory–Generic Core (n = 27), CareQol (n = 26), and Pediatric Quality of Life Inventory–Family Impact (n = 27), communication abilities, as well as social functioning and activities of daily living, were noted to be most impacted.

Through the use of standardized surveys and outcome assessments, we establish the effects of β-propeller protein–associated neurodegeneration on caregiver quality of life. Key health concepts identified by families included overall health, comfort, and communication. The identified HC will inform the future identification of concept of interest and selection of appropriate clinical outcome assessments through the administration of patient-reported outcomes.

Keywords

disability outcome pediatric quality of life

Get full access to this article

View all access options for this article.

References

Hor

CHH

Tang

. Beta-propeller protein-associated neurodegeneration (BPAN) as a genetically simple model of multifaceted neuropathology resulting from defects in autophagy. Rev Neurosci. 2019;30(3):261-277. doi:https://doi.org/10.1515/revneuro-2018-0045

Haack

Hogarth

Gregory

Prokisch

Hayflick

. BPAN: The only X-linked dominant NBIA disorder. Int Rev Neurobiol. 2013;110:85-90. doi:https://doi.org/10.1016/b978-0-12-410502-7.00005-3

Pereira

Dória

. X-chromosome inactivation: implications in human disease. J Genet. 2021;100(2).

Adang

Pizzino

Malhotra

, et al. Phenotypic and imaging spectrum associated with WDR45. Pediatr Neurol. 2020;109:56–62. doi:https://doi.org/10.1016/j.pediatrneurol.2020.03.005

Gavazzi

Pierce

Vithayathil

, et al. Psychometric outcome measures in beta-propeller protein-associated neurodegeneration (BPAN). Mol Genet Metab. 2022;137(1-2):26-32. doi:https://doi.org/10.1016/j.ymgme.2022.07.009

Long

Abdeen

Geraghty

Hogarth

Hayflick

Venkateswaran

. Novel WDR45 mutation and pathognomonic BPAN imaging in a young female with mild cognitive delay. Pediatrics. 2015;136(3):e714-e717. doi:https://doi.org/10.1542/peds.2015-0750

Haack

Hogarth

Kruer

, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. The American Journal of Human Genetics. 2012;91(6):1144-1149. doi:https://doi.org/10.1016/j.ajhg.2012.10.019

Sandilands

Williams

Rylands

. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet J Rare Dis. 2022;17(1). doi:https://doi.org/10.1186/s13023-022-02561-w

Van Hezik-Wester

Handels

RLH

Wolfs

CAG

Kanters

. Caregiver burden and quality of life across Alzheimer’s disease severity stages. Alzheimer Disease & Associated Disorders. 2023;37(2):134-141. doi:https://doi.org/10.1097/wad.0000000000000558

10.

Dellve

Samuelsson

Tallborn

Fasth

Hallberg

LRM

. Stress and well-being among parents of children with rare diseases: a prospective intervention study. J Adv Nurs. 2006;53(4):392-402. doi:https://doi.org/10.1111/j.1365-2648.2006.03736.x

11.

The burden of Alzheimer's disease. Int J Neuropsuchopharmacolog. 2000. doi:https://doi.org/10.1093/ijnp/3.supplement_2.s31

12.

Yang

Cintina

Pariser

Oehrlein

Sullivan

Kennedy

. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1). doi:https://doi.org/10.1186/s13023-022-02299-5

13.

Carlozzi

Kallen

Hanks

, et al. The TBI-CareQOL measurement system: Development and preliminary validation of health-related quality of life measures for caregivers of civilians and service members/veterans with traumatic brain injury. Arch Phys Med Rehabil. 2019;100(4S):S1-S12. doi:https://doi.org/10.1016/j.apmr.2018.08.175

14.

Narayanan

Fehlings

Weir

Knights

Kiran

Campbell

. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol. 2006;48(10):804-812. doi:https://doi.org/10.1017/s0012162206001745

15.

Avoine-Blondin

Parent

Lahaye

Humbert

Duval

Sultan

. Identifying domains of quality of life in children with cancer undergoing palliative care: a qualitative study with professionals. Palliative and Supportive Care. 2017;15(5):565–574. doi:https://doi.org/10.1017/s1478951516001048

16.

Focus Area: Patient-Reported Outcomes and other Clinical Outcome Assessments. US Food and Drug Administration. Accessed January 28, 2024. https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments

17.

Kempf

Goldsmith

Temple

. Challenges of developing and conducting clinical trials in rare disorders. American Journal of Medical Genetics Part A. 2018;176(4):773-783. doi:https://doi.org/10.1002/ajmg.a.38413

18.

Bridges

Crossnohere

Schuster

Miller

Pastorini

Aslakson

. A patient and community-centered approach selecting endpoints for a randomized trial of a novel advance care planning tool. Patient Prefer Adherence. 2018;12:241-249. doi:https://doi.org/10.2147/ppa.s150663

19.

FDA Patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. Accessed April 3, 2024. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical

20.

Goldberg

Dill

Shin

Nguyen

. Reliability and validity of the Vietnamese Vineland Adaptive Behavior Scales with preschool-age children. Res Dev Disabil. 2009;30(3):592-602. doi:https://doi.org/10.1016/j.ridd.2008.09.001

21.

Varni

Limbers

. The pediatric quality of life inventory: Measuring pediatric health-related quality of life from the perspective of children and their parents. Pediatr Clin North Am. 2009;56(4):843-863. doi:https://doi.org/10.1016/j.pcl.2009.05.016

22.

Varni

Seid

Kurtin

. PedsQL 4.0: Reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800-812. doi:https://doi.org/10.1097/00005650-200108000-00006

23.

Varni

Sherman

Burwinkle

Dickinson

Dixon

. Health Qual Life Outcomes. 2004;2(1):55. doi:https://doi.org/10.1186/1477-7525-2-55

24.

Harris

Taylor

Thielke

Payne

Gonzalez

Conde

. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi:https://doi.org/10.1016/j.jbi.2008.08.010

25.

Harris

Taylor

Minor

, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:https://doi.org/10.1016/j.jbi.2019.103208

26.

Landis

Koch

. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.

27.

Wilson

Gregory

Kurian

, et al. Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration. Dev Med Child Neurol. 2021;63(12):1402-1409. doi:https://doi.org/10.1111/dmcn.14980

28.

Ashwal

Russman

Blasco

, et al. Practice parameter: Diagnostic assessment of the child with cerebral palsy: Report of the quality standards subcommittee of the American Academy of Neurology and the practice committee of the Child Neurology Society. Neurology. 2004;62(6):851-863. doi:https://doi.org/10.1212/01.wnl.0000117981.35364.1b

29.

Ammann-Schnell

Groeschel

Kehrer

Frölich

Krägeloh-Mann

. The impact of severe rare chronic neurological disease in childhood on the quality of life of families—a study on MLD and PCH2. Orphanet J Rare Dis. 2021;16(1):211. doi:https://doi.org/10.1186/s13023-021-01828-y

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

Determination of Health Concepts in β-Propeller Protein–Associated Neurodegeneration

Abstract

Keywords

Get full access to this article

References

Supplementary Material